305 related articles for article (PubMed ID: 11585295)
1. Antithyroid drugs as a factor influencing the outcome of radioiodine therapy in Graves' disease and toxic nodular goitre?
Körber C; Schneider P; Körber-Hafner N; Hänscheid H; Reiners C
Eur J Nucl Med; 2001 Sep; 28(9):1360-4. PubMed ID: 11585295
[TBL] [Abstract][Full Text] [Related]
2. Different strategies to overcome the effect of carbimazole on high- and low-dose radioiodine therapy: results from continuous dose-effect models.
Walter MA; Schindler C; Christ-Crain M; Müller-Brand J; Müller B
Eur J Clin Invest; 2009 Jan; 39(1):51-7. PubMed ID: 19087129
[TBL] [Abstract][Full Text] [Related]
3. Influence of antithyroid drugs on the outcome of radioiodine therapy in Graves' disease and toxic nodular goitre.
Sabri O; Zimny M; Buell U
Eur J Nucl Med Mol Imaging; 2002 Jan; 29(1):160-1. PubMed ID: 11807618
[No Abstract] [Full Text] [Related]
4. Radioiodine therapy in Graves' disease patients with large diffuse goiters treated with or without carbimazole at the time of radioiodine therapy.
Sabri O; Zimny M; Schreckenberger M; Reinartz P; Ostwald E; Buell U
Thyroid; 1999 Dec; 9(12):1181-8. PubMed ID: 10646656
[TBL] [Abstract][Full Text] [Related]
5. Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements.
Berg GE; Michanek AM; Holmberg EC; Fink M
J Nucl Med; 1996 Feb; 37(2):228-32. PubMed ID: 8667049
[TBL] [Abstract][Full Text] [Related]
6. The influence of non-radioactive iodine (127I) on the outcome of radioiodine (131I) therapy in patients with Graves' disease and toxic nodular goitre.
Rogowski F; Abdelrazek S; Szumowski P; Zonenberg A; Parfienczyk A; Sawicka A
Nucl Med Rev Cent East Eur; 2011; 14(1):9-15. PubMed ID: 21751166
[TBL] [Abstract][Full Text] [Related]
7. Radioiodine therapy compared in patients with toxic nodular or Graves' hyperthyroidism.
Franklyn JA; Daykin J; Holder R; Sheppard MC
QJM; 1995 Mar; 88(3):175-80. PubMed ID: 7767667
[TBL] [Abstract][Full Text] [Related]
8. Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy.
Antonelli A; Rotondi M; Fallahi P; Romagnani P; Ferrari SM; Barani L; Ferrannini E; Serio M
Clin Endocrinol (Oxf); 2006 Feb; 64(2):189-95. PubMed ID: 16430719
[TBL] [Abstract][Full Text] [Related]
9. The effect of antithyroid drug pretreatment on acute changes in thyroid hormone levels after (131)I ablation for Graves' disease.
Burch HB; Solomon BL; Cooper DS; Ferguson P; Walpert N; Howard R
J Clin Endocrinol Metab; 2001 Jul; 86(7):3016-21. PubMed ID: 11443161
[TBL] [Abstract][Full Text] [Related]
10. Outcome of treatment of hyperthyroidism.
Bringmann IM; van Leeuwen BL; Hennemann G; Beckett GJ; Toft AD
J Endocrinol Invest; 1999 Apr; 22(4):250-6. PubMed ID: 10342357
[TBL] [Abstract][Full Text] [Related]
11. A randomized trial evaluating a block-replacement regimen during radioiodine therapy.
Bonnema SJ; Grupe P; Boel-Jørgensen H; Brix TH; Hegedüs L
Eur J Clin Invest; 2011 Jul; 41(7):693-702. PubMed ID: 21175612
[TBL] [Abstract][Full Text] [Related]
12. Outcome of 131I therapy in hyperthyroidism using a 550MBq fixed dose regimen.
Lewis A; Atkinson B; Bell P; Courtney H; McCance D; Mullan K; Hunter S
Ulster Med J; 2013 May; 82(2):85-8. PubMed ID: 24082285
[TBL] [Abstract][Full Text] [Related]
13. Does an individual estimation of halflife improve the results of radioiodine therapy of Graves' disease?
Schneider P; Körber C; Körber-Hafner N; Hänscheid H; Reiners C
Nuklearmedizin; 2002 Dec; 41(6):240-4. PubMed ID: 12520660
[TBL] [Abstract][Full Text] [Related]
14. Antithyroid drug treatment prior to radioiodine therapy for Graves' disease: yes or no?
Bogazzi F; Martino E; Bartalena L
J Endocrinol Invest; 2003 Feb; 26(2):174-6. PubMed ID: 12739747
[No Abstract] [Full Text] [Related]
15. Serum cytokines in thyrotoxicosis.
Siddiqi A; Monson JP; Wood DF; Besser GM; Burrin JM
J Clin Endocrinol Metab; 1999 Feb; 84(2):435-9. PubMed ID: 10022397
[TBL] [Abstract][Full Text] [Related]
16. Late and transient increases in free T4 after radioiodine treatment for Graves' disease.
Stensvold AD; Jorde R; Sundsfjord J
J Endocrinol Invest; 1997 Nov; 20(10):580-4. PubMed ID: 9438914
[TBL] [Abstract][Full Text] [Related]
17. The effect of methimazole pretreatment on the efficacy of radioactive iodine therapy in Graves' hyperthyroidism: one-year follow-up of a prospective, randomized study.
Andrade VA; Gross JL; Maia AL
J Clin Endocrinol Metab; 2001 Aug; 86(8):3488-93. PubMed ID: 11502768
[TBL] [Abstract][Full Text] [Related]
18. Iodine-131 given for therapeutic purposes modulates differently interferon-gamma-inducible alpha-chemokine CXCL10 serum levels in patients with active Graves' disease or toxic nodular goiter.
Antonelli A; Rotondi M; Fallahi P; Grosso M; Boni G; Ferrari SM; Romagnani P; Serio M; Mariani G; Ferrannini E
J Clin Endocrinol Metab; 2007 Apr; 92(4):1485-90. PubMed ID: 17244787
[TBL] [Abstract][Full Text] [Related]
19. Radioiodine therapy versus antithyroid medications for Graves' disease.
Ma C; Xie J; Wang H; Li J; Chen S
Cochrane Database Syst Rev; 2016 Feb; 2(2):CD010094. PubMed ID: 26891370
[TBL] [Abstract][Full Text] [Related]
20. Discordant hypothyroxinemia and hypertriiodothyroninemia in treated patients with hyperthyroid Graves' disease and toxic multinodular goiter.
Gedik O; Ozdemir T; Akalin S
Isr J Med Sci; 1991 Jul; 27(7):361-4. PubMed ID: 1712765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]